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Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by
extensive deposition of amyloid plaques in the brain. These plaques contain an amyloid
fibril core that is formed through self-aggregation of the P-amyloid peptide (AP), a
proteolytic product of amyloid precursor protein (APP). AP aggregation is currently
thought to play a causative role in the development of AD, and thus is an attractive target
for potential therapeutics. A library of pharmaceutically active compounds (LOPAC) was
screened for potential inhibitors of AP aggregation using a 96 -well microplate assay. No
inhibitors were found in the library, but, surprisingly, several compounds exhibited a
stimulatory effect on AP deposition. Two of the most potent·stimulatory compounds from
the library (NPC 15437 and calmidazolium chloride) were chosen for more detailed
studies, with the hope that they might offer some insight into mechanistic and structural
aspects of AP aggregation, as well as providing possible ideas for drug development.
NPC 15437 was found to stimulate the nucleation phase of AP aggregation in a
concentration dependent manner through an interaction with monomeric AP peptide.
Calmidazolium chloride at a concentration of 100 µM was observed to stimulate the
formation of an aggregated state of AP that is clearly distinct from mature amyloid
fibrils. Based on these findings the compounds described here (a) could possibly offer
insight into the mechanism by which amyloid is formed, as well as the chemical
structures that are important to amyloid formation, (b) could be used to test the amyloid
hypothesis in mouse models of AD, and (c) may be of some importance in the
development of AD therapeutics
IV
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I. Background

Amyloidosis is the term for a series of diseases involving soluble proteins
aggregated into highly ordered structures termed amyloid fibrils [Sipe, 1 9 9 2 # 1]. Rudolf
Virchow first applied the term "amyloid" - meaning "starchlike" - to these diseases in
1853 based on the staining properties of extracellular deposits in human tissue [Selkoe,
1 9 9 1 # 2]. However, it is now known that amyloid deposits are actually composed of
proteins, and that they have several common features. They have a high content of P
pleated sheet secondary structure, as well as a high affinity for the histochemical stain
Congo red and the fluorescent dye thioflavin T (ThT) [Sipe, 1 9 9 2 # 1]. They are also
insoluble under physiologic conditions, and are resistant to proteolytic digestion [Sipe,
1 9 9 2 # 1].
Amyloidosis occurs m many human diseases, including type II diabetes,
Creutzfeldt-Jakob Disease, rheumatoid arthritis, Huntington's Disease (HD), and
Alzheimer's Disease (AD) [O'Brien, 2000 #3]. The peptide associated with the amyloid
deposits in AD is the amyloid P-protein (AP) [Selkoe, 1 9 9 1 # 2]. AP exists in many
forms, ranging from39 to 43 amino acids in length [Gandy, 1 9 9 2 #4]. It is a product of
the cleavage of the larger membrane bound amyloid precursor protein (APP) [Selkoe,
1 98 9 #5 ]. The precise physiological function of APP is unknown, although there is a
consensus sequence present at the carboxy terminus that is known to mediate endocytosis
of cell surface proteins [O'Brien, 2000 #3]. It is possible that APP function is related to
neuronal repair and regeneration [O'Brien, 2000 #3].
One hypothesis that has gained popularity is that AP deposition in plaques in
brain tissue is the causative factor in AD, and that all other pathological symptoms
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(neurofibrillary tangles, cell loss, vascular damage, and dementia) follow as a result of
this initial deposition [Hardy, 2002 #6]. Most of the strong evidence in favor of this
hypothesis is genetic. Early onset forms of AD have been observed to cosegregate with
mutations in APP [Hardy, 2002 #6]. Most of these mutations have been found to map at
or near cleavage sites in the primary sequence of APP that are targeted by the proteases
P- and y- secretase, and therefore generate AP by favoring proteolytic processing of APP
[Hardy, 2002 #6]. Other familial AD causing mutations that are internal to the AP
sequence have been linked to changes in aggregation kinetics [Hardy, 2002 #6]. In
addition, the gene encoding APP has been localized to chromosome 21, and individuals
with trisomy 21 (Down's Syndrome) inevitably exhibit the neuropathology of AD
[Masters, 1985 #7]). It is assumed that the third copy of chromosome 21 leads to higher
levels of AP [Masters, 1985 #7]. Finally, the other known autosomal dominant gene
mutations that cause early onset AD, the presenilin mutations, have been shown to
increase the production of AP(l-42) [Hardy, 2002 #6]. The presenilin genes (PS1 and
PS2) may alter AP� metabolism by a direct effect on y-secretase [Hardy, 2002 #6]. All of
these observations are consistent with the theory that AP aggregation plays a causative
role in AD.
However, there are some concerns with the amyloid hypothesis. For example, the
number of amyloid deposits in AD brains does not always correlate with the amount of
cognitive impairment, while deposition of tau protein in neurofibrillary tangles does ·seem
to correlate with it [Hardy, 2002 #6]. However, recent findings have suggested that tau
alterations occur after alterations in APP processing, and also that AP toxicity is tau
2

dependent [Hardy, 200 2 #6]. These observations have led to a theory that smaller
aggregated forms of AP may in fact be the true disease causing agents [Hardy, 200 2 #6].
Thus, it seems reasonable that drug design strategies that target either AP production or
AP aggregation are viable therapeutic approaches [Esler, 1 9 9 7 #8].
To be able to target AP aggregation as a therapeutic approach, it is necessary to
understand the stages and kinetics of AP fibrillization. The pathway of aggregation of AP
from peptide to amyloid fibril appears to involve quaternary structural intermediates
[Kelly, 1 9 98 # 9]. Circular dichroism (CD) has shown that AP fibrils are rich in P-sheet
secondary structure [Harper, 1 9 9 7 # 10] of a specific type called a "cross-P" conformation
[Serpell, 2000 # 1 1]. Fibrils also show a high amount of protection against hydrogen
deuterium exchange of the amide protons along the peptide backbone, which has been
attributed to extensive hydrogen bonding in the P-sheet core of the fibrils [Kheterpal,
2000 # 1 2].
Analytical ultracentrifugation, electron microscopy, atomic force microscopy, and
light scattering have all shown that AP( 1 -4 0 ) at concentrations well above the critical
concentration (Cr) (see below) exists as both high weight fibrillar oligomers, and also
slightly lower weight oligomers [Harper, 1997 #10 ]. The presence of the smaller
oligomeric form of AP(l-40 ) suggests that the fibril assembly pathway of AP(l-40 )
involves discrete intermediates [Harper, 1 9 9 7 # 10 ]. These intermediates have been
visualized by electron microscopy [Nybo, 1 9 9 9 # 14]. The earliest observed intermediates
are globular aggregates about 4 -5 nm in diameter [Nybo, 1 9 9 9 # 14 ]. These intermediates
then associate to form short protofilaments ( 10 -20 nm in diameter), which in tum form
3

protofibrils, and subsequently amyloid fibrils through lateral association [Nybo, 1999
#14].
Protofibrillar structures have been observed in the polymerization of both AP(140) and AP(l-42), suggesting that they are a common intermediate in all AP
fibrillogenesis [Walsh, 1997 #15]. Proto fibrils have also been shown to be less resistant
to hydrogen-deuterium exchange (I. Kheterpal and H. Lashuel, unpublished) than fibrils
[Kheterpal, 2000 #12], suggesting that early intermediates are not as rich in P-sheet
structure as fully formed fibrils. It has also been shown that formation of an oligomeric,
a-helix rich intermediate is common to fibril formation in 18 forms of AP peptide
[K.irkitadze, 2001 #16]. It is not clear which intermediate on the fibril formation pathway,
if any, this a-helical structure represents and its significance in fibrillogenesis remains a
matter of debate [Kirkitadze, 2001 #16]. It should be noted that all of the observed
intermediates (early globular aggregates, protofilaments, and protofibrils) have only been
seen in vitro. Even so, there is still a possibility that these non-amyloid oligomeric
intermediates may be the toxic species in AP amyloidosis [Walsh, 1997 #15]. If so,
protofibrils would be an attractive target for potential therapeutic agents.
The presence of a protofibrillar intermediate has been interpreted as being
consistent with the theory that AP aggregation follows a nucleation dependent pathway
[Harper, 1997 #10]. Several features characterize nucleation dependent polymerization.
First, there is no aggregation at peptide concentrations below the critical concentration
(Cr) [Harper, 1997 #10]. The critical concentration is defined as the concentration of
peptide at which the rates of fibril formation and fibril dissolution are equal [Harper,
4

1 9 97 #10]. Second, at peptide concentrations that are slightly higher than Cr, there is a lag
time before aggregation begins [Harper, 1 9 97 #10]. Lag time is defined as the time before
amyloid formation occurs during which the peptide remains soluble [Harper, 1 9 97 #1 O].
Finally, during the lag time, addition of a small amount of fibril seed results in immediate
aggregation. Nucleation dependent aggregation is thermodynamically similar to micelle
formation with respect to the critical concentration, but kinetically is much slower,
possibly because the process is more complex, and there is a much greater entropic
barrier to fibril organization [Harper, 1 9 97 #1 O].
There are thus three main steps involved in nucleation dependent pathways (see
Scheme 1 ). The first step, also known as the "nucleation" step, involves conversion of the
monomer peptide to a thermodynamically unstable "nucleus" that is presumed to be
oligomeric [Harper, 1 9 97 #10]. During this step, molecules collide to form transitory,
highly unstable complexes [Harper, 1 9 97 #10]. The nucleus is the least stable oligomer
on the assembly pathway. As more monomer is incorporated in elongation steps, that
oligomer becomes more stable. Once the oligomeric nucleus contains more than the
critical number of molecules, its continued growth leads to the formation of more and
more stable aggregates, featuring less and less tendency to dissociate to monomer
[Harper, 1 9 97 #1 O]. After the formation of this "critical nucleus" comes the "elongation"

• •
• ••
• •
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annular aggregates

Scheme 1 Amyloid fibril formation
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step of the pathway [Harper, 1997 #1O]. During this step, where addition of further
monomers is thermodynamically favorable (see above), rapid extension of the aggregates
occurs [Harper, 1997 #10] according to pseudo first order kinetics (first order in both
monomer and fibril growing ends, with the latter unchanging over the course of the
reaction). The final phase of the pathway occurs when the peptide monomer is depleted
to the point where fibril growth and dissolution are in a dynamic equilibrium [Harper,
1997 #10].
Fibril growth is more complex in vivo, however. For instance, factors such as
chemical damage and binding of other proteins can render fibrils stable to dissociation
[Harper, 1997 #10]. For example, apolipoprotein E2 (apoE2) is an endogenous protein
that has been shown to inhibit amyloid fibril formation [Harper, 1997 #10]. Also, cellular
concentrations of AP are much lower in vivo than those typically used in vitro, which
makes it unclear how nucleation can occur in vivo [Harper, 1997 #10]. It may be possible
that nucleation occurs in cellular organelles with a supersaturated AP concentration, and
fibrils formed in this way can then be released from the cellular compartment and act as
seeds for additional fibril formation [Harper, 1997 #1 O].
A number of assays have been developed for following amyloid fibril growth in
vitro [Levine, 1999 #17]. One assay that can be used to monitor spontaneous aggregation

of AP in solution monitors the change in fluorescence that accompanies ThT binding to
fibrillar aggregates [Levine, 1999 #17]. This assay can be used to monitor either
unseeded AP aggregation (nucleation and elongation phases of aggregation), or seeded
AP aggregation (elongation phase of aggregation) [Naiki, 1999 #18]. Another assay
[Esler, 1997 #8] that has been developed uses a 96 well microplate to monitor deposition
6

of AP monomer onto an immobilized fibrillar template. The microplate assay is similar to
the ThT assay of seeded AP aggregation, except that the fibril seeds are immobilized on a
plastic swface. One benefit of the microplate assay is that it can be used with peptide
concentrations on the order of 10 nM, as opposed to the ThT assay, which uses peptide
concentrations of 30 µM. Also, the microplate assay offers a much higher throughput
than the ThT assay.
High throughput assays such as the microplate assay described above [Esler, 1997
#8] lend themselves well to drug screening. In the drug screening process, a large number
of pharmaceutically active chemicals can be tested in a biological system to determine
which, if any, exhibit an effect on that system [Esler, 1997 #8]. For example, high
throughput screening identified a small molecule that activates caspase-3 in cancer cells,
and this discovery in turn revealed information about the regulatory pathways in tumor
suppressor activity and apoptosis in these cancer cells [Jiang, 2003 #20]. High throughput
screening has also been used to look for potential therapeutics in Alzheimer's disease
[Reixach #21, Esler #8] by looking for compounds that affect AP fibril formation.
Inhibition of AP aggregation is a very appealing target for drug design [Lansbury,
1997 #22]. Studies have shown that AP immunizations in murine models of Alzheimer's
disease reduce both the level of fibrillar AP deposition in the brain and the level of
cognitive decline [Janus, 2000 #23]. These findings suggest that there is a link between
AP aggregation/deposition in the brain and cognitive decline in Alzheimer's disease.
Therefore, screening libraries of compounds for inhibitors of AP aggregation and/or
deposition could lead to the discovery of novel drug candidates for treating Alzheimer's.
7

Interpretation of the results of such screens is complicated, however, due to the
uncertainty about what the toxic aggregate is (i.e., the possibility that an intermediate on
the fibril assembly pathway may be the toxic species, while mature amyloid fibrils may
actually be protective) [Hardy, 200 2 #6].
The high throughput microplate assay described previously [Esler, 1 9 97 #8] can
be used to screen a large number of compounds for potential inhibitors of AP deposition.
A similar assay has been developed to screen for inhibitors of aggregation of the amyloid
peptide polyglutamine (polyQ) [Berthelier, 200 1 # 24]. The biggest advantage of this
assay over the assay described in [Esler, 1 9 97 #8] is that it avoids the use of radioactivity.
This assay has been adapted to identification of inhibitors of AP aggregation (R. Wetzel,
unpublished).
Using this assay, we set out to identify inhibitors from a collection of compounds
that had been prepared for use in drug screening. The Library of Pharmaceutically Active
Compounds (LOPAC) from Sigma was screened for potential inhibitors. The LOPAC
library contains 640 pharmaceutically active compounds dissolved in dimethyl sulfoxide
(DMSO). The choice of DMSO in the library is because of its "universal solvent"
properties. If the solubility limit of each compound in the library had to be determined
individually, the overall assay process would bog down, despite the existence of a high
throughput assay. In fact, not all compounds are soluble in 100% DMSO, and some
compounds have limited solubility when diluted from DMSO into an aqueous buffer.
However, the loss of some potentially useful compounds due to solubility issues is
outweighed by the gains in sheer numbers that accompany high throughput analysis.
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When the LOPAC library was screened for potential inhibitors of polyQ
aggregation, several were found (V. Berthelier, T. Richey, unpublished). The use of the
AP version of this microplate assay to screen the LOPAC library is described here. In
fact, no inhibitors of AP were identified. Instead, several compounds were found that
apparently stimulate deposition of AP in vitro. These compounds, whose discovery and
preliminary characterization are also described here, may offer insight into the
mechanism of AP aggregation, and possibly help elucidate the three dimensional
structure of AP aggregates. Compounds in these classes may also prove to be important
therapeutics, if they are stimulating the formation of a non-toxic aggregated state of AP.
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II. Materials and Methods
Peptides. AP (1 -40) peptide was obtained by custom solid phase synthesis from the Keck

Biotechnology Center at Yale University. The biotinylated form of the peptide was
prepared ( R. Wetzel, unpublished) by alkylation of the sulthydryl group of Cys· 1 -AP( l40) with PEO-iodoacetyl biotin ( Pierce, Rockford, IL).
D isaggregation and solubilization of AJ} (1-40) peptides. Disaggregation and

solubilization of AP (1-40 ) peptide was performed as described previously [Jao, 199 7
#25]. Thus, AJ} (1-40) peptide was dissolved in trifluoroacetic acid ( TFA) ( Pierce,
Rockford, IL) at a concentration of1 mg/ml and sonicated for15 minutes to remove any
remaining aggregates. The TFA was then evaporated under a stream of argon in a fume
hood. The peptide residue was then solubilized in 1 1, , l,3 3, 3, - hexafluoro-2- propanol
( HFIP) ( Sigma, St. Louis, MO) at a concentration of1 mg/ml and incubated for one hour
at3 7°C. At this point, the HFIP was evaporated under a stream of argon in a fume hood,
and the peptide residue solubilized once more in HFIP at 1 mg/ml, and the solution
aliquoted into test tubes with 0.5 mg of AP (1 -40) per test tube. The solvent in each test
tube was evaporated under argon, and the peptide residue was placed under vacuum for
one hour to remove any remaining TFA and HFIP. The peptide residue was then
dissolved at a concentration of0.5 mg/ml in1 X PBS at a pH of 7.4 and this solution was
centrifuged at 100 0, 00 g for1 7 hours to remove any aggregated peptide. The supernatant
was collected, and the exact concentration of AP (1 -40) determined by reverse phase high
performance liquid chromatography ( RP-HPLC) ( Hewlett- Packard, Palo Alto, CA) using
a Zorbax SB- C3 column on an Agilent system1100. Thus,10 µL of solubilized peptide,
10

diluted 10 times in 0.1% TFA, was injected onto the column and analyzed with a 0-5 0%
(v/v) acetonitrile gradient in 0.05% TFA applied at a rate of 2% per minute. The· peak
area obtained at 215 nm was compared to a standard curve previously established with
AJ3 (1-40) whose concentration had been determined independently by amino acid
composition analysis. All peptides were snap-frozen and stored at -80°C prior to use.
Preparation of AP ( 1-40 ) fibrils. AJ3 (1-40) peptide solubilized as described above was

adjusted to a concentration of 28. 9 µM (0.125 mg/ml) in buffer containing PBS I X and
NaN3 0.05% and incubated at 37°C. After 14 days, the fibrils were collected by
centrifuging at 20,000g for 25 minutes and resuspended in extension buffer (PBS I X,
0. 01% tween 20, and 0.05% NaN3). The quality of the fibrils was checked by thioflavin-T
(ThT) fluorescence and electron microscopy (EM). An aliquot of the fibrils was dissolved
in TFA, and the exact concentration of the fibrils was determined using RP-HPLC to
determine the amount of AP in the aliquot as described above. The fibrils were then
sonicated for 5 minutes, snap-frozen in liquid nitrogen, and stored at -80°C.
Microplate preparation. AP (1-40) fibrils prepared as described above (or other AJ3

aggregates, as described below) were fixed to activated ELISA 96-well microtiter plates
(EIAIRIA Plates, Costar, Atlanta, GA) by passive adsorption. The microplates were
incubated uncovered at 37°C for 17 hours with 100 µL of AP (1-40) fibrils diluted to a
concentration of 1 µg/ml in 72 wells, which gave 100 ng of AJ3 (1-40) fibrils per well,
and 100 µL of extension buffer in the remaining 24 wells as a negative control to
measure any background signal. After the 17 hour incubation, the wells were washed
three times with extension buffer, incubated for one hour at 37°C with 100 µL of 0. 3%
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(w/v) gelatin in extension buffer to block any remaining surfaces in the wells not bound
with fibrils, and again washed three times with extension buffer. The microplates were
used immediately following this treatment.
Kinetics assay. Prior to the assay, 90 µL of extension buffer was added to each well. For

kinetic measurements with compounds, 80 µL of extension buffer was added to each
well, followed by 10 µL of compound dissolved in DMSO (at an appropriate
concentration) prior to starting the extension assay. For each replicate of each time point,
10 µL of 100 nM biotinyl-AP (1-40) was added to the wells, after which the plate was
covered with an adhesive overlay and incubated at 37°C. Each time point was analyzed in
triplicate (three wells) in reverse temporal order. Thus, the wells which have biotinyl-AP
(1-40) added at the start of the assay will give the longest time point of the data. At each
subsequent time point, the plate was removed from the incubator and uncovered, 10 µL
of 100 nM biotinyl-AP (1-40) was added to the next set of wells, and the plate was re
covered and returned to the incubator. This process was repeated until all of the intended
time points had been set up.
Microplate signal generation. After the incubation for the final time point, the extension

reactions were stopped simultaneously by washing each well three times with extension
buffer using the stream from a wash bottle. To generate the signal for the microplate,
each well was then incubated for one hour at room temperature with 100 µL of a 100
ng/mL europium-streptavidin (EG&G Wallac, Gaithersburg, MD) solution in extension
buffer containing 0.5% bovine serum albumin (S igma) (BSA). After this incubation, the
wells were washed three times with extension buffer, and the europium was released
12

from the streptavidin by adding 1 00 µL of an enhancement solution (EG&G Wallac)
[Hemmila, 1 984 #26] . After 5 minutes, the europium was measured by time-resolved
fluorometry [Dimandis, 1 988 #27] in a Victor 2 (EG&G Wallac) microtiter plate reader
using the programmed parameters for counting europium. Europium counts obtained by
this method were converted to fmoles of europium using a standard curve obtained with a
standard europium solution from EG&G Wallac (not shown). Fmoles of europium were
then converted to fmoles of biotinyl-AP ( 1 -40) using the manufacturer determined ratio
+

of 7 Eu3 ions per streptavidin molecule.
Primary screen of LOPAC library. The LOPAC library (Sigma, St. Louis, MO) is
provided in eight 96 well plates. Each plate has 80 wells containing pharmaceutically
active compounds dissolved at concentrations of 1 mM in 1 00% dimethyl sulfoxide
(DMSO), and 1 6 wells containing pure DMSO as controls. For the screening of each
plate in the library by the extension assay, three microplates were coated with AP ( 1 -40)
fibrils, as described above, for triplicate measurements. 80 µL of extension buffer was
added to all of the wells in each plate, followed by 1 0 µL of the LOPAC library solutions
in the wells corresponding to their position in the LOPAC library plates, giving a final
concentration of 1 00 µM compound in each well. Next, 1 0 µL of 1 00 nM biotinyl-AP
was added to each well. The microplates were then incubated at 3 7°C for thirty minutes.
The extension reaction was then stopped by washing each well three times with extension
buffer, and the signal for each plate was generated as described above.
Dose response studies. Microplates were coated with AP (1 -40) fibrils as described
above, and 90 µL of compounds that showed a stimulatory effect on AP ( 1 -40) extension
13

in the primary screen of the LOPAC library were added to the wells at concentrations
ranging from O to 1 00 µM in extension buffer containing 1 0% DMSO. Each
concentration of compound was added to three wells for triplicate measurements. Next,
1 0 µL of 1 00 nM biotinyl-AP was added to each well. The microplates were then
incubated at 3 7°C for thirty minutes.

The extension reaction was then stopped by

washing each well three times with extension buffer, and the signal for each plate was
generated as described above.
Washout assay. Microplates were coated with AP ( 1 -40) fibrils as described above, and

90 µL of compounds that showed a stimulatory effect on AP ( 1 -40) extension in the
primary screen of the LOPAC library were added to the wells at a concentration of 1 00
µM in extension buffer containing 1 0% DMSO. The microplate was incubated at 25 °C
for 60 minutes. The compounds were removed from the microplate by washing each
well three times with extension buffer. In one set of three wells, the kinetic assay was
conducted as described above. 1 00 µL of extension buffer was added to another set of
three wells, incubated at 25°C for 1 20 minutes, and washed three times with extension
buffer. The kinetic assay was then conducted as described above.
Solution phase aggregation assays. The most potent compounds from the LOP AC

library as determined by the dose response studies were purchased from Sigma for more
detailed study (see Results section). To determine the effect of these compounds on AP
( 1 -40) aggregation kinetics in solution, AP (1 -40) rigorously disaggregated as described
above was incubated at 28.9 µM in PBSA ( I X PBS, 0.05% NaN3 ) buffer with compound
concentrations ranging from O to 1 00 µM. As a control, AP ( 1 -40) was also incubated at
14

28 .9 µM in PBSA at37°C in the presence of fibril seeds at 0 .05% the weight of AP (140 ) monomer in the reaction. The aggregation kinetics were followed by ThT
fluorescence measurements [Levine, 1 9 9 9 # 17], by RP-HPLC analysis [Naiki, 1 9 9 9 # 18],
and by 90 ° light scattering at 45 0 nm [Wood, 1 9 9 6 # 1 9] as described previously. Thus, a
ThT fluorescence signal was generated by diluting a 10 µL aliquot of each reaction
solution to a final volume of 400 µL in PBSA containing 15 µM ThT, and measuring
fluorescence of the sample in a fluorometer with the excitation wavelength set to 44 2 nm
and the emission wavelength set to 48 2 nm. The fluorescence data for each time point
was collected over one minute, and then averaged. Each time point was analyzed in
triplicate. For RP-HPLC analysis, a30 µL aliquot of each reaction was diluted5 -fold into
ice-cold PBSA to stop the aggregation reaction, put on ice, and centrifuged at 100 ,000 g
for 25 minutes at 4 °C. The upper 100 µL of the supernatant was collected, and TFA
added to a concentration of 1% (v/v). The sample was then analyzed for the amount of
soluble AP (1 -4 0 ) by RP-HPLC as described above. 90 ° light scattering measurements
for each sample were obtained by diluting a 10 µL aliquot of each reaction solution to a
final volume of400 µL in PBSA and measuring the light scattering with excitation and
emission wavelengths both set to 450 nm and slit widths set to1 0 nm. To determine the
effect of the compounds on the structure of the AP (1 -4 0 ) aggregation products, aliquots
of each reaction mixture were collected after 2 days and after 14 days and analyzed by
electron microscopy. All electron micrographs were generated by the Life Sciences
Electron Microscopy Facility at the University of Tennessee, Knoxville.
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Collection and storage of aggregates. Aggregates were collected by centrifuging

aliquots of various time points for each solution phase reaction at 20,000g for 25 minutes
at 4°C, removing the supernatant, and resuspending the pellet in PBSA. This process was
repeated three times to remove any remaining unbound compound from the reaction
mixture. The exact concentration of the Af3 (1-40) aggregates was determined by
centrifuging an aliquot of the resuspended pellet, and dissolving in TFA as described
above, and measuring the concentration of Af3 (1-40) by RP-HPLC as described above.
The resuspended pellet was then snap-frozen, and stored at -80°C until used.
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III. Results

Since AP aggregation is implicated in the disease mechanism of Alzheimer's
disease, compounds that influence AP aggregation may be potential therapeutics. A
microtiter plate assay for AP extension has been developed (R. Wetzel, unpublished)
which provides a high throughput way of screening large numbers of potential inhibitors.
Figure 1 shows the typical kinetic time course observed in this assay 1 . The time course is
characterized by an initial fast phase of extension, and a second slow phase of extension.
We decided to conduct the primary screen of the Library of Pharmaceutically Active
Compounds (LOPAC) by stopping the extension reaction after 30 minutes, which
corresponds approximately to the midpoint of the fast phase. The LOPAC library
contains 640 pharmaceutically active compounds dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 100 µM. Thus, dilution of the compound solutions into
aqueous buffer will produce a mixed aqueous solvent containing a small amount of
DMSO which could potentially influence the assay results. DMSO has been shown,
h�wever, to have no effect on the analogous kinetic determination of polyglutamine
elongation as observed in the microtiter plate assay [Berthelier, 2001 # 24 ]. Figure 2
shows that similarly there is no significant effect of DMSO up to a10% concentration on
AP extension in the microtiter plate assay after30 minutes.
Figure3 shows the results of the primary screen of the LOPAC library, with each
bar on the graph representing one compound. The percent inhibition of each compound is
calculated by the equation
(1 )
1

I = [(Cn - Ci)/Cn]* l00

All figures are located in the Appendix.
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where
I = Percent inhibition
C 0 = Amount of biotinyl-AP deposited in absence of compound
Ci = Amount of biotinyl-AP deposited in presence of compound
Surprisingly, none of the compounds in the LOPAC library showed any significant
inhibition (greater than three standard deviations from the average) of AP deposition in
the microplate assay. However, seven compounds actually stimulated (showed a negative
percent inhibition of) deposition of Ap. The compounds - amiloride HCl, phenamil
methane

sulfonate,

naftopidil

dihydrochloride,

NPC

1 543 7

dihydrochloride,

calmidazolium chloride (R2457 1 ), 5-(nonoxyl)-tryptamine hydrogen oxalate, and L-a
methyl DOPA - have a wide variety of structures and biochemical properties (see
Discussion section). The structures of these seven compounds are shown in Figure 4,
along with the percent stimulation observed in our experiments. Even though the only
hits observed in the initial screen exhibited stimulatory effects, they could still prove
useful in gaining information about the biochemical process of AP aggregation (see
Discussion).
Interestingly, several catechol-containing compounds, similar in structure to L-a
methyl DOPA, were initially identified as modulators of a-synuclein fibrilization, and
were also identified as inhibitors of polyglutamine aggregation (V. Berthelier,
unpublished). In both cases, it was subsequently determined that the species acting as the
inhibitor was actually the oxidized quinone form of the compound [Conway, 200 1 #28] .
Since the LOPAC library had been stored prior to the screen, it may be possible that a
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similar oxidized form of L-a.-methyl DOPA is the active species in AJ3 aggregation
stimulation as well (see Discussion section). However, no experiments were performed to
test this hypothesis. One reason for this is that the stimulation exhibited by L-a.-methyl
DOPA was marginal, compared to some of the other compounds (see below).
As part of the overall screening process, it is important to examine the
concentration dependence of the hits. Figure 5 shows the results of such dose response
studies (see Materials and Methods) for each of the seven compounds. The
concentrations of the compounds in the dose response studies ranged from 0 .05 to 100
µM. Interestingly, only calmidazolium chloride showed a saturation effect for stimulation
in this concentration range (Figure 5 C). Calmidazolium chloride shows maximal
stimulation at a concentration of5 0 µM, while the stimulation of the other six compounds
still appear to be increasing even at concentrations of 100 µM.
Compound potencies are described as ECso values. The ECso value of a
compound is defined as the compound concentration at which the measured effect is half
maximal. The transition region of each dose response curve is identified as the region in
which the percent stimulation begins to increase from values corresponding to no effect.
Fitting the data points in the transition zone to a straight line through a linear regression
gives an equation that can be used to calculate an ECso value for each compound.
However, because calmidazolium was the only one of the seven compounds that showed
a saturation effect (and hence a plateau such that a maximal effect could clearly be seen),
it is the only compound for which a true ECso could be calculated. That is to say, since
the effects of the other six compounds at concentrations higher than 100 µM were never
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determined, it may be possible that the calculated EC50 values are underestimates of the
true EC50 values. Figure 5 shows the straight line fits for the transition region of each
dose response curve, while the apparent EC50 values for each compound are given in
Figure 4. Based on the calculated EC5o values of the seven compounds, calmidazolium
chloride (EC50 = 2 1.4 µM), NPC 15 437 (ECso � 27.2 µM), phenamil methane sulfonate
(EC50 � 35. 5 µM), and 5-(nonyloxy)-tryptamine hydrogen oxalate (ECso �30 3
. µM) are
the most potent stimulators of A� deposition. L-cx-methyl DOPA (ECso �34.2 µM) is the
least potent stimulator.
Three of the four most potent compounds - calmidazolium chloride, NPC 15437,
and phenamil methane sulfonate - are readily available from Sigma, and were therefore
chosen for more detailed study. Amiloride HCl was also chosen for additional study
because structurally (a) it very closely resembles phenamil methane sulfonate (Figures
4 A and 4 B), and (b) both compounds have structural elements suggestive of peptide
bonds, which play a significant role in the formation of the �-sheet structure of fibrils.
Once compounds have been identified in the initial screening process, it is important to
obtain fresh compounds for further testing for two main reasons. First, testing fresh
compounds makes sure that no mix-ups occurred in the original screening, and second, it
can identify problems with long term storage of the compounds in DMSO (e.g. oxidation
of dihydroquinones to quinones mentioned above). All four compounds to be retested
were purchased from Sigma.
First, we set out to confirm the behavior of these apparent stimulators by
conducting full kinetic analyses of each compound (rather than one time point) in the
microplate assay. Figure 6 A shows the kinetic time course of A� deposition in the
20

microplate assay in the presence and absence of calmidazolium chloride. The results
show that calmidazolium chloride significantly increases the rate of deposition, as well as
the amount of Af3 deposited. Figure6B shows the kinetic time course of Af3 deposition in
the microplate assay in the presence and absence of NPC 1543 7. These results show that
NPC 1543 7 also stimulates both the rate and amplitude of the kinetic curve, although not
as potently as calmidazolium.
Figures 6C and 6D show similar kinetic time course data for amiloride HCl and
phenamil methane sulfonate. These two figures show that freshly dissolved amiloride
HCl and phenamil methane sulfonate appear to have an inhibitory effect on the kinetics
of Af3 deposition in the microplate assay. The contradiction between this result
( inhibition) and the initial screening result ( stimulation) for these two compounds may be
due to the fact that they were not stored in DMSO for any length of time prior to the
assay, in contrast to the compounds in the LOPAC library that had been stored for several
months in DMSO prior to the primary screen. The storage of the compounds for an
extended period of time may have led to a degradation product of amiloride and
phenamil, which are highly similar structurally, and the degradation product may be the
species responsible for the stimulation of Af3 deposition in the primary screen. In any
case, the apparent inhibition by these two compounds was not great enough to warrant
further investigations, and they were not studied further.
The solid phase microtiter format allows an assay modification that can be used to
probe which molecular species is the target of the compounds' activity. This
modification, termed the "washout assay" ( see Materials and Methods) can be used to test
whether the stimulating effects of calmidazolium chloride and NPC 1543 7 in the
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microplate assay were due to interactions with the preformed fibrillar AP on the plate or
with the solution-phase biotinyl-AP. The washout assay has been used successfully in
studying inhibitors of polyglutamine aggregation to show that the inhibitors act through
interactions with the polyglutamine aggregates rather than the monomer (V. Berthelier,
unpublished). The washout assay results for NPC 15437 are shown in Figure 7. These
results show that washing the wells that had been incubated with NPC 15437
immediately prior to starting the extension assay gives a kinetic time course that is
virtually indistinguishable from the kinetic time course of AP deposition in the absence
of the compound. However, in the continual presence ofNPC 15437 an amplified kinetic
curve is observed. The rates and amplitudes of both phases of this kinetic curve are
significantly greater than those observed in the absence of NPC 15437. Also, absolutely
no deposition of AP is observed when biotinyl-AP is incubated with NPC 15437 in the
absence of a preformed fibrillar template (Figure 7B). These results suggest that NPC
15437 is stimulating deposition of AP through some sort of interaction with the AP
monomer, and that if there is any non-covalent binding between NPC 15437 and fibrillar
AP aggregates then that binding is very weak.
Figure 8 shows the results of the washout assay for calmidazolium chloride. The
results of the washout assay indicate that calmidazolium chloride stimulates AP
deposition even if it is removed from the solution phase prior to the extension assay.
However, the stimulatory effect is decreased when the wells are incubated in extension
buffer for two hours after the removal of the compound before starting the assay.
Together these results suggest that (a) calmidazolium acts by binding to the fibrillar AP
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aggregates and (b) that this binding is not extremely tight, since some compound can
dissociate after incubation of the plate in extension buffer for two hours.
As a control in the washout assay, some microtiter plate wells without
immobilized fibril seeds were incubated for 4 hours at 3 7°C with a solution of biotinyl
AP plus calmidazolium. Surprisingly, strong two phase kinetics are obtained even in the
absence of a preformed fibrillar template, as shown in Figure 9 . There are a number of
possible explanations for this unexpected effect.

For example, it is possible that

calmidazolium interacts with the gelatin blocking agent in the microplate wells,
converting the gelatin to a fibril-like seed capable of being elongated with Ap. However,
Figure 10 shows that even without a preformed fibrillar template, AP deposition is
stimulated in the presence of calmidazolium regardless of whether the microplate wells
. % gelatin buffer or with 0 5. %BSA buffer. However, calmidazolium
are blocked with 0 3
does not stimulate AP deposition as greatly in microplate wells blocked with 0 5. % BSA,
and it does not show strong two phase kinetics. The fact that calmidazolium still
stimulates AP deposition in microplate wells blocked with 0 5. % BSA suggests that
calmidazolium does not act through a direct effect on the blocking agent. Another
possibility is that calmidazolium is acting via an interaction with the monomeric Ap. It
should be noted, however, that to produce this effect calmidazolium must not only
stimulate AP aggregation, but it must also stimulate the deposition of the aggregates on
the plate. In addition, these aggregates must be elongation competent, but it is not clear
from these experiments whether or not this is the case. To better understand the nature of
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the effect that calmidazolium has on AP aggregation, it is necessary to use additional
assays.
The microplate assay acts as an in vitro model of the elongation phase of AP
aggregation. Solution phase assays have also been described [Levine, 1999 #17] that act
as in vitro models of spontaneous aggregation ( both the nucleation and elongation
phases) of AP. These solution phase assays are important for several reasons. First, they
can be used to confirm that the microplate results are accurate. Second, they can reveal
whether the effect of the compounds on the nucleation phase of aggregation is different
than the effect on the elongation phase. And finally, they offer a way to further explore
the mechanism of calmidazolium action on AP .
These assays depend on the ability to monitor fibril growth either directly - by
monitoring ThT fluorescence [Levine, 1999 #17] - or indirectly - by monitoring the
depletion of AP monomer by HPLC [Naiki, 1999 #18 ]. To use the ThT assay, we first
had to confirm that the test compounds have no effect on fluorescence under assay
conditions. Figure11 shows that calmidazolium chloride has no significant effect on ThT
fluorescence at concentrations ranging from 0 1. µM to1 mM in the presence or absence
of AP fibrils. Similarly, Figure 12 shows that NPC 15437 has no significant effect on
ThT fluorescence over the same concentration range. Therefore, fibril growth in the
presence of each compound can be monitored by ThT fluorescence without having to
correct for high background signals due to direct fluorescence effects of the compounds.
Figure 13 A shows the kinetic time course of AP aggregation monitored by ThT
fluorescence in the presence of NPC15437 at concentrations ranging from O to100 µM,
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while Figure 13B shows the kinetic time courses for the same aggregation reactions
monitored by RP-HPLC. Interestingly, the ThT results show that as the concentration of
NPC 15437 is increased, the lag time to aggregation is decreased. This suggests that NPC
15437 is acting by stimulating nucleation of amyloid fibril formation by the AP
monomer. However, even at NPC 15437 concentrations of 100 µM there is still a lag
time of approximately 4 days. As the ThT signal increases to a maximum, the level of AP
left in solution drops to a base level. These results suggest that NPC 15437 does indeed
stimulate the nucleation stage of AP aggregation.
It is also interesting that, contrary to previous observations [Wood, 1 9 9 6 # 1 9]
when measured by RP-HPLC the level of AP monomer decreases well before any ThT
signal develops, even in the absence of NPC 15437. One possible explanation for this
result is that the reaction aliquots were centrifuged at 100 ,000 g for 25 minutes to remove
any aggregated AP (see Materials and Methods) as opposed to 14 ,000 g as described
previously [Wood, 1 9 9 6 # 1 9]. Thus, it is possible that early intermediates on the pathway
from AP monomer to fibril are only removed by extremely rigorous centrifugation and
that the formation of these intermediates, if they are ThT negative, would account for the
decrease in monomeric Ap. Non-fibrillar aggregates are clearly present at the 2 -day
point, as shown in Figure 14 . The secondary structure of AP fibrillogenesis intermediates
is difficult to measure, and there is currently no consensus on the extent to which
protofibril substructure resembles that of fibrils [Kirkitadze, 200 1 # 1 6]. At the end of the
lag phase the ThT and RP-HPLC results shown in Figures 13A and 13 B seem to agree.
The correspondence between the results of the ThT and RP-HPLC assays after the lag
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phase suggests that the bulk of the aggregates formed in the presence of NPC 154 37 are
indeed fibrillar, in direct contrast to the results for calmidazolium ( see below).
Figures 16, 17, and 18 show EM images of AP aggregates grown for fourteen
days in the presence of NPC 15437 at concentrations ranging from O to 100 µM. These
aggregates show structures very similar to those of fibrils grown in the absence of any
compound ( Figure 15). In fact, the aggregates grown in the presence of 10 µM NPC
15437 ( Figure 17) appear to be even larger than untreated aggregates ( Figure 14 ). It may
be possible that NPC 15437 is somehow acting to stabilize the fibrillar state of the AP
aggregates and enabling them to grow larger than usual. It may also be possible that NPC
15437 is somehow stabilizing key intermediates in the fibrillization pathway, thereby
altering their steady state concentrations and in tum changing the observed rate.
Isothermal titration calorimetry experiments did not indicate a titration between NPC
15437 and AP up to a molar ratio ( NPC/AP) of50 ( data not shown). It is also possible
that this compound is destabilizing off- pathway AP assemblies, effectively increasing the
concentration of AP monomer or of some other critical on-pathway intermediates.
Figure 19 shows the kinetic time course of AP aggregation monitored by ThT
fluorescence in the presence of calmidazolium chloride at concentrations ranging from O
to 100 µM. Interestingly, after 14 days the ThT signal of fibrils grown in the presence of
100 µM calmidazolium chloride has an intensity that is approximately 25% of the
intensity of the ThT signal of fibrils grown in the absence of calmidazolium.
Furthermore, as the concentration of calmidazolium is lowered, the intensity of the ThT
signal increases. This suggests that the AP aggregates formed in the presence of
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calmidazolium are significantly less fibril-like than fibrils grown normally, since ThT
fluorescence is proportional to the amount of fibrils present [Levine, 1 999 # 1 7] .
Figure 2 0 shows .the kinetic time course o f AP aggregation monitored by RP
HPLC in the presence of calmidazolium chloride at concentrations ranging from 0 to 1 00
µM. These results show that calmidazolium at a concentration of 1 00 µM completely
depletes the AP monomer in solution after only one day. However, Figure 1 9 shows that
at the same time point under these reaction conditions, no appreciable ThT signal can be
seen. This suggests that calmidazolium is driving AP into an aggregated state that is not
amyloid. This profile is similar to that implied by the lack of ThT signal observed for
early AP assembly intermediates in the absence of added compound (see above).
Figure 2 1 shows the kinetic time course of AP aggregation monitored by 90° light
scattering at 450 nm. It is interesting that only AP aggregates grown in the presence of
1 00 µM calmidazolium show any appreciable light scattering signal. The light scattering
of these aggregates appears after one day, which fits with the data obtained by RP-HPLC.
It also supports the theory that AP is rapidly aggregating in the presence of 1 00 µM
calmidazolium.
To get a more detailed look at the early events due to the effect of calmidazolium,
the reactions were repeated and hourly time point measurements taken. Figure 22A
shows the hourly time course of AP aggregation monitored by light scattering at 450 nm,
while Figure 22B shows the same hourly time course as monitored by RP-HPLC.
Interestingly, after only two hours the RP-HPLC measurement of the AP monomer
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remaining in solution decreases from an initial value, while at the same time point, the
light scattering signal increases from a baseline.
Based on the RP-HPLC data, AP monomer m the presence of 1 00 µM
calmidazolium is significantly depleted almost within 1 -2 hours (Figures 22B). This
depletion of monomer is accompanied by a simultaneous increase in light scattering
(Figures 2 1 and 22A). Also, after one day at these reaction conditions a precipitate is
observed. However, this precipitate is not the test compound, since no precipitate is
formed when calmidazolium is incubated in buffer without AP present (not shown).
These results indicate that calmidazolium is indeed stimulating aggregation of AP in
solution. However, there is a significant reduction in the ThT signal of these aggregates
compared to an equal weight of bona fide fibrils (Figure 1 9). One possibility that could
reconcile these apparently contradictory observations is that calmidazolium is acting
somehow to drive the AP monomer into a non-fibrillar aggregated state. The implication
that calmidazolium stimulates aggregation of AP in a non-fibrillar form is not
inconsistent with the original microplate result, because the microplate generates a
positive signal for AP deposition regardless of whether or not the deposited product is
fibrillar (see Materials and Methods).
Electron microscope (EM) images of AP aggregates grown for two days and AP
aggregates grown for fourteen days at calmidazolium chloride concentrations ranging
from O to 1 00 µM are shown in Figures 23 through 28. Figure 1 4 shows that after two
days, aggregates grown in the absence of calmidazolium show globular structures similar
to those reported by others for AP amyloid assembly (see Background), and very few
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fibrils. However, Figure 23 shows that after two days, aggregates grown at a
calmidazolium chloride concentration of 100 µM are very large, and do not appear to be
fibrillar (although these globular assemblies appear to contain short, filamentous
substructures). Figure 2 4 shows that after two days, aggregates grown at a calmidazolium
concentration of 10 µM have a more ordered structure than aggregates grown without
calmidazolium, but these structures are not as large as those seen in aggregates grown in
100 µM calmidazolium. Compared to the EM images of the control fibrils (Figure 15 ),
none of these aggregates appear to be fibrillar, which agrees with the ThT data (Figure
1 9 ). However, Figure 25 shows that after two days, Af3 aggregates grown in the presence
of 1 µM calmidazolium appear to be highly fibrillar. This suggests that calmidazolium at
concentrations below 10 µM enhances Af3 fibril formation, perhaps by stabilizing key
intermediates in the amyloid assembly pathway. Circular dichroism experiments to
determine the amount of (3-sheet secondary structure in the non-fibrillar aggregates
proved unsuccessful, due to the large amount of light scattering associated with them
(data not shown).
Figure 15 shows the structure of fibrils grown in the absence of calmidazolium
chloride after fourteen days. Figure 2 6 shows the structure of aggregates grown in the
presence of 100 µM calmidazolium after the same amount of time. Interestingly, the large
aggregated structures present after two days at these reaction conditions are still present,
but fibrillar aggregates are now also present. At calmidazolium concentrations of 10 and
1 µM, the aggregated structures all appear to be fibrillar (Figures 27 and 28 ). From the
EM images, it seems as though 100 µM calmidazolium is indeed driving Af3 into a non-
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fibrillar aggregated state after only one day. However, after fourteen days AP fibrils are
also present under these conditions, as seen in Figure 26. This could possibly be caused
by the non-fibrillar AP aggregates rearranging to form fibrils, either by a direct
transformation within the solid phase, or mediated by a small amount of solution phase

If the aggregates that form rapidly in the presence of calmidazolium are indeed
non-fibrillar, then they should exhibit no ability to seed wild type AP fibril
formation/elongation. We tested the seeding ability of aggregates formed in the presence
of calmidazolium using the microplate assay. Aggregates grown in the presence of
calmidazolium at concentrations of 0 , 10 , and 100 µM were collected as described in
Materials and Methods after two days and fourteen days. These aggregates were washed,
calibrated for weight concentration, and immobilized on a 96 well microplate (see
Materials and Methods) to test their seeding ability. Figure 2 9 A shows the kinetic time
course of AP deposition onto equal weights of the aggregates grown in the presence of
100 µM calmidazolium for two days and fourteen days, compared to the kinetic time
course of AP deposition on equal weights of standard AP amyloid fibrils grown for the
same periods of time. These results show that after two days aggregates grown in the
presence of 100 µM calmidazolium cannot seed deposition of AP in the microplate assay.
After fourteen days these aggregates show some seeding ability, but it is very limited
compared to the seeding ability of normal AP fibrils grown for fourteen days. This lack
of seeding ability agrees qualitatively with the results of the ThT assay. It is also
consistent with the hypothesis that calmidazolium is driving AP monomer into a non30

fibrillar aggregated state. The seeding ability of the calmidazolium aggregates after 14
days could possibly be due to the presence of a small amount of fibrillar AP that forms
either from AP in solution that does not interact with calmidazolium, or by a
rearrangement of the AP that is associated with calmidazolium. The partial seeding of AP
elongation by 14-day AP/calmidazolium aggregates fits with the fibrillar and globular
structures observed by EM in the 14 day calmidazolium aggregates (Figure 26).
Figure 29B shows the kinetic time course of AP deposition onto the aggregates
grown in the presence of 10 µM calmidazolium for two days and fourteen days compared
to the kinetic time course of AP deposition onto normal fibrils grown for the same
periods of time. These results show that aggregates grown in the presence of 10 µM
calmidazolium for two days also cannot seed AP deposition in the microplate assay. After
fourteen days, however, these aggregates do show some seeding ability, although it is not
nearly as great as that of normal fibrils grown for the same amount of time.
We also set out to test the hypothesis that calmidazolium stimulates deposition of
elongation competent aggregates in the microplate assay ( see above) by incubating
gelatin blocked microplate wells at 37°C for 1 hour with either both 10 nM AP (non
biotinylated) and I 00 µM calmidazolium chloride, only 10 nM A� (non-biotinylated), or
only 100 µM calmidazolium chloride, then washing the wells with buffer, and conducting
the microplate assay as described in Materials and Methods (Figure 30). The results of
this test showed no AP extension after incubating the microplate wells with any
combination of AP and calmidazolium, which suggests that calmidazolium is simply
stimulating deposition of biotinyl-AP in the microplate wells, and the method of signal
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generation in the assay (see Materials and Methods) creates a signal for the deposited
biotinyl-AP, regardless of whether or not it is fibrillar.
In addition to testing the seeding ability of these AP/calmidazolium aggregates,
we also checked the level of protection from hydrogen/deuterium exchange of the
aggregates. It has been shown that, in AP(l -40) fibrils, about 50% of the 39 backbone
amide protons of AP are strongly protected from deuterium exchange, indicating that
about 19 of the protons are involved in stable P-sheet structure. [Kheterpal, 2000 #12,
Kheterpal, 2003 #13]. Figure 31A shows that AP aggregates grown in the presence of
100 µM calmidazolium even after 14 days undergo hydrogen exchange much more
readily than do AP fibrils. This result suggests that the amide groups of the AP peptides
in these AP /calmidazolium aggregates are much more exposed to solvent than those of
fibrils, and that the network of hydrogen bonds is not as great as in fibrils. This might be
attributed to there being less P-sheet secondary structure present in these aggregates
compared to AP fibrils (see Background). The amount of protection seen for these
calmidazolium aggregates is essentially identical to that seen for AP protofibrils isolated
from the normal in vitro assembly reaction (I. Kheterpal and H. Lashuel, unpublished).
As shown in Figure 31B AP/10 µM calmidazolium aggregates also exchange to the same
degree as the AP /100 µM calmidazolium aggregates and protofibrils up to four days, but
after fourteen days, they more closely resemble AP fibrils in terms of the amount of
exposure to solvent. Could calmidazolium be stimulating the formation of a protofibrillar
intermediate which is less strongly blocked from rearranging into fibrils at lower
calmidazolium concentrations? If so, it could prove to be a valuable research tool in
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further exploring the A� fibril assembly pathway, as well as the amyloid hypothesis (see
Background).
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IV. Discussion

Inhibition of the aggregation of amyloidogenic peptides is an attractive target for
potential drugs to treat the diseases associated with those peptides [Lansbury, 1997 #22].
High throughput assays have been developed to screen a very large number of
compounds for potential inhibitors of these amyloidogenic systems ([Berthelier, 2001
#24], [Esler, 1997 #8]). However, these assays can also identify compounds that
stimulate the aggregation of amyloid, as is the case with this work. Such stimulatory
compounds have a number of potential uses. First, these compounds are of interest to
researchers because studying their interaction with the amyloidogenic species can
possibly offer insight into the mechanism by which amyloid is formed, as well as the
chemical structures that are important to amyloid formation. Second, these compounds
could be used to test the amyloid hypothesis. Do mouse models treated with these
compounds develop Alzheimer's Disease pathology and/or cognitive defects more
rapidly than normal? Alternatively, if the compounds stimulate deposition of a non-toxic
form of A�, do they slow disease progress in the mouse model? If so, they could
potentially be useful as therapeutics.
The compounds identified in this study that stimulate A� aggregation in vitro can
be divided into four classes based on their chemical structures (Figure 4). The first class
is comprised of compounds containing cyclical structures of carbon and nitrogen. These
compounds are amiloride HCl,

phenamil methane sulfonate,

and naftopidil

dihydrochloride. Interestingly, amiloride and phenamil are structural analogs. Phenamil
has the basic chemical structure of amiloride with a benzene ring attached at one of the
nitrogen atoms. Also, based on the ECso values, phenamil is approximately as potent as
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amiloride (ECso � 38.5µM and 3 5.5 µM respectively). Another interesting aspect of these
two compounds is the fact that portions of their structures resemble a peptide bond (an a
carbon atom between C-N and ·c=0 atoms). Unfortunately, the stimulating effect of these
compounds is not reproducible when they are freshly dissolved in DMSO (see Figures
5A and 5B). This could be due to the fact that the compounds in the LOP AC library were
stored in DMSO at 4°C for several months prior to the primary screen. It is possible that
degradation products of these two compounds were responsible for the stimulation of
aggregation observed in the primary screen. This possibility was not explored in this
work.
The second class of stimulators contains L-a-methyl DOPA. The catechol
containing structure is similar to those of other compounds that have been identified as
modulators of aggregation of the amyloid a-synuclein [Conway, 200 1 #28] and inhibitors
of polyglutamine aggregation (V. Berthelier, unpublished). In this previous work it was
shown that the oxidized quinone forms of the catechol containing compounds are the
active species [Conway, 200 1 #28] . It may be possible that a similar oxidized form of L
a-methyl DOPA is responsible for the results in the primary screen of the LOP AC
library. However, it is worth noting that the LOPAC library contained 1 2 catechol-like
structures very similar to L-a-methyl DOPA, none of which had any effect on AP
deposition in the microplate assay in our primary screen. Therefore, L-a-methyl DOPA
may indeed be interacting with AP in the microplate assay, but due to the fact that it is
not a very potent stimulator (ECso � 34.2 µM) and the possibility that an oxidized form of
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the compound is indeed the active stimulating species, the uses of L-a-methyl DOPA in
further studies of AJ3 aggregation would be very limited.
The third class of stimulators contains NPC 15437 and 5-(nonyloxy)-tryptamine
hydrogen oxalate. These compounds both have amphipathic characteristics. They each
contain long hydrophobic carbohydrate chains and primary amino groups that are
presumably protonated at pH 7 (see Figures 4A and 4B). They are also both very potent
(EC 5o 2::: 27.2 µM and 30.3 µM respectively). The amphipathic molecule hexadecyl-N
methylpiperidinium (HMP) has been found to inhibit in vitro fibril formation [Wood,
1996 #29]; this work was conducted in a pH 6 aggregation system, however, and is
therefore difficult to compare to results described here. It is unclear whether the
amphipathic characteristics of NPC 1543 7 and 5-(nonyloxy)-tryptamine hydrogen oxalate
are primarily responsible for their stimulatory effects on AP deposition. As compounds
likely to form micelles, it is possible that such micelles are the actual species responsible
for stimulating AP aggregation in vitro. However, light scattering experiments to
determine a critical micelle concentration (CMC) for NPC 15437 proved unsuccessful
(data not shown). NPC 15437 seems to stimulate the nucleation phase of AJ3 aggregation
(see Figure 13A), but it is unclear from the present data what the exact mechanism of
stimulation by NPC 1543 7 might be. One possibility is that NPC 1543 7 alters the
stabilities of key intermediates in the fibril assembly pathway, thereby altering the steady
state concentrations of intermediates, which in tum would affect the observed rate of
aggregation.
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The final class of compound contains calmidazolium chloride. Calmidazolium is
highly hydrophobic, with four phenyl groups attached to a central imidazole ring (see
Figure 4C). Calmidazolium is also the most potent of the seven stimulators presented
here (ECso = 21.4). Interestingly, when the LOPAC library was screened for inhibitors of
polyglutamine (polyQ) aggregation, calmidazolium had no effect on the rate of
aggregation up to a concentration of 100 µM (V. Berthelier, T. Richey, unpublished).
This result suggests that there is an intrinsic mechanistic and/or structural difference
between polyQ and AP amyloid aggregation, despite the many similarities also seen for
these aggregates.
It is noteworthy that even though some compounds in the LOPAC library have
been found to inhibit polyglutamine aggregation in the microplate assay (V. Berthelier, T.
Richey, unpublished), none of them showed any inhibitory effect on AP aggregation in
the same assay. Even more interesting is the fact that there were quite a few compounds
in the LOPAC library that actually stimulated AP aggregation in the microplate assay,
and none in the polyglutamine screen, again suggesting that the mechanisms of assembly
and/or structural stabilization of different amyloid proteins, or the roles of various amino
acid residues of the peptide in their assembly, are quite different from one another.
At least two different mechanisms of stimulation of AP aggregation have been
characterized here, both of which are apparently due to interactions with non-amyloid
states of AP (monomer and/or protofibrils). This result is exciting, as it could provide
valuable insight into the basic mechanism of AP assembly. Also exciting is the fact that
based on RP-HPLC and light scattering data, AP in the presence of calmidazolium forms
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aggregates after only one day while EM images and ThT fluorescence measurements
show that these aggregates do not appear to be fibrillar in nature. Is calmidazolium
driving AP into a non-toxic, non-amyloidogenic conformation? If so, are there any other
compounds that have the same properties as calmidazolium chloride (i.e., the ability to
stimulate formation of a non-fibrillar AP aggregate)? It may be likely that there are other
compounds similar to calmidazolium, since this work only looked at approximately 600
out of millions of chemical compounds. If there are compounds with properties similar to
calmidazolium, then there may be potential therapeutic applications of them. However,
much work must be done to determine if this is a viable option or not. For instance, if
calmidazolium truly is a potential therapeutic then it must be determined if it can act at
physiologically relevant concentrations of AP. The microplate assay is conducted at I 0
nM AP, while the concentration of AP in blood and cerebrospinal fluid is in the low pM
range [Harper, 1997 #10]. It is also necessary to determine whether calmidazolium is
stimulating the formation of a toxic aggregated state of Ap.
Additionally, the results from the microplate assay indicate that calmidazolium in
the presence of AP at a concentration of 10 nM stimulates aggregation instantaneously,
but in the ThT assay at AP concentrations of 30 µM there is a delay before fibrils can be
seen. The most likely explanation for this result is that the microplate assay detects all AP
deposited (see Materials and Methods), regardless of whether or not it is fibrillar. The
signal in the ThT assay only appears once fibrils are present. Also, as shown in Figure
22B, AP in the presence of I 00 µM calmidazolium in the solution phase assay is depleted
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after only a few hours, which is consistent with the instantaneous effect seen in the
microplate assay.
Calmidazolium chloride could prove to be a valuable tool in testing the amyloid
hypothesis in a mouse model of AD. For instance, if protofibrils are the toxic species in
the amyloid pathway and calmidazolium is stimulating their formation, would mouse
models treated with calmidazolium be more prone to the neurodegenerative effects of
AD, or would calmidazolium keep the protofibrils clustered in a large aggregated state
that is non-toxic to cells? Also, if the toxic species is an intermediate in the amyloid
assembly pathway, and calmidazolium is actually stimulating fibril formation as it
originally appeared in the microplate assay, then it may actually prevent the accumulation
of these intermediates. Of course, there is still the possibility that mouse models that are
treated with calmidazolium will develop AD more rapidly than normal. The results of
these mouse model experiments will undoubtedly give additional insight into the action
of calmidazolium, and they will be important in developing potential therapeutics, but
will likely not be immediately interpretable. In any case, calmidazolium could eventually
give useful information about the role that AP plays in AD.
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Figure 1 Kinetic time course of A� deposition in microplate assay (conducted as
described in Materials and Methods). The "fast phase" of elongation occurs over the first
60 minutes, followed by the "slow phase".
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Figure 2 Effect of DMSO on A� microplate extension assay (as described in Materials
and Methods) at 30 minute time point. Results shown are average of three replicates.
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Figure 3 Results of primary screen of LOPAC library. Results shown are average of
triplicate measurements for each compound after 30 minutes. Stimulatory compounds
exhibit negative inhibition. Vertical lines represent three standard deviations.
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(A)

(C)

(B)

(D )

(E)

Figure 4 Compounds exhibiting stimulation of A� aggregation in initial screen of

LOPAC library (see Materials and Methods). A - Amiloride HCI. Initial stimulation
. µM. B - Phenamil methane sulfonate. Initial stimulation
observed = 96%; EC 5o � 38 5
observed = 242%; EC 50 2:: 35.5 µM. C - Calmidazolium chloride. Initial stimulation
observed = 598 %; ECso = 21 4. µM. D - Naftopidil dihydrochloride. Initial stimulation
observed =150 %; ECso � 36.2 µM. E - L-a-methyl DOPA. Initial stimulation observed
. µM.
=127%; EC5o �34 2
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(G)

(F)

Figure 4 (cont.) F - 5-(nonyloxy)-tryptamine hydrogen oxalate. Initial stimulation
observed = 1 36%; EC 50 � 30.3 µM. G - NPC 1 5437. Initial Stimulation observed =
1 49%; EC so � 27 .2 µM.
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Figure 6 Effect of stimulatory compounds on AP deposition in microplate assay
(conducted as described in Materials and Methods). A - Kinetic time course of AP
deposition in presence ( ■) and absence ( A ) of 100 µM calmidazolium. B - Kinetic time
course of AP deposition in presence (■) and absence ( A ) of 100 µM NPC 1543 7. C Kinetic time course of AP deposition in microplate assay in presence (■ ) and absence
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kinetic time courses shown in the absence of compound were obtained on one microplate
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Figure 7 Washout assay results for NPC 1 5437. The washout assay was conducted as
described in Materials and Methods. A - Kinetic time course of AP deposition in
microplate wells incubated with 1 00 µM NPC 1 5437 for 60 minutes followed by
incubation in buffer for 2 hours prior to the assay (♦ ), in wells incubated with 1 00 µM
NPC 1 5437 for 60 minutes immediately prior to the assay (1■), and wells with no NPC
1 5437 present ( • ). B - Kinetic time course of AP deposition in microplate wells with
1 00 µM NPC 1 5437 and fibrils present (■), wells with 1 00 µM NPC 1 5437 and no fibrils
present ( ♦), and wells with fibrils and no NPC 1 5437 present ( • ).
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Figure 8 Washout assay results for calmidazolium chloride ( conducted as described in
Materials and Methods). Kinetic time courses shown represent AP deposition in wells
incubated with100 µM calmidazolium for60 minutes followed by a 2 hour incubation in
buffer prior to the assay ( ♦), wells incubated with100 µM calmidazolium for60 minutes
immediately prior to the assay ( ■), and wells with no calmidazolium present during the
assay ( A ). The kinetic time courses shown here were obtained on the same day, and from
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54

.c

.....0

<(

-

.c
0

E

It-

10

•

8

6
4

2
0

I

'• I

�

0

-.- -

.JI

1

/

---.

--------•

�

200

1 00

T i me (mi n )

300
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Figure 10 Lack of influence of blocking agent on calmidazolium chloride stimulatory
effect. A - Kinetic time course of AP deposition on microplates blocked with 0.3%
gelatin. B - Kinetic time course of AP deposition on microplates blocked with 0.5%
BSA. No fibrils were present in any of the microplate wells. The washout assay was
conducted for each microplate as described in Materials and Methods. Results are shown
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Figure 14 AP aggregates grown in absence of compound after 2 days.
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Figure 15 Al} aggregates (fibrils) grown in absence of compound after 14 days.
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Figure 16 AJ3 fibrils grown in presence of 100 µM NPC 15437 after 14 days.
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Figure 17 AJ3 fibrils grown in presence of1 0 µM NPC 154 37 after 14 days.
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Figure 18 AJ3 fibrils grown in presence of 1 µM NPC 15437 after 14 days.
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Figure 1 9 Effect of calmidazolium chloride on unseeded A� aggregation as measured by
ThT fluorescence (see Materials and Methods). 30 µM A� in I X PBS present in each
aggregation reaction. Data points shown represent reactions with no calmidazolium
present (--+-), 100 µM calmidazolium present (•), 30 µM calmidazolium present (*), 20
µM calmidazolium present (+), 10 µM calmidazolium present ( • ), and 1 µM
calmidazolium present ( ■).
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Figure 20 Effect of calmidazolium chloride on AP aggregation as measured by RP
HPLC (see Materials and Methods). 30 µM AP in lX PBS present in each aggregation
reaction. Data points shown represent unseeded (--+-) and seeded (..._) controls with no
calmidazolium present, and unseeded reactions with 1 00 µM calmidazolium (•) and 1
µM calmidazolium (■) present.
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Figure 21 Effect of calmidazolium chloride on unseeded AP aggregation as measured by
90° light scattering at 450 nm (see Materials and Methods). 30 µM AP in l X PBS present
in each aggregation reaction. Data points represent AP aggregation in the absence of
calmidazolium (♦ ), in the presence of 1 00 µM calmidazolium ( • ), in the presence of 20
µM calmidazolium ( • ), in the presence of 1 0 µM calmidazolium ( ■ ), and in the presence
of 1 µM calmidazolium (X).

70

(A)
200

�

'5

E

I

1 &)

■

■

- '

0

�

0

-&>

■

■

•

a

■

1 00
&)

■

■

•

1

5

7

6

8

Time (hr)

(B)
0. 14
_ 0. 1 2
..J
::::s

a
2.

j

0.1

rt •••

0.08

0

§ 0.06

E

J! 0.04

•

A

A

A

A

3

4

5

6

7

• • • • •
■ •
• ■ :■ ■
I■

A

< 0.02

0
0

1

2

8

Time (hr)

F igure 22 Effect of calmidazolium chloride on early stages of AJ3 aggregation. A - AP
aggregation as monitored by light scattering at 450 nm ( conducted as described in
Materials and Methods). B - As monitored by RP-HPLC ( conducted as described in
Materials and Methods). Data points shown represent unseeded ( • ) and seeded ( ♦) AJ3
aggregation reactions, and unseeded AJ3 aggregation in the presence of 1 00 µM
calmidazolium ( ■).
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Figure 23 AP aggregates grown in presence of 1 00 µM calmidazolium after 2 days.
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Figure 24 Afl aggregates grown in presence of IO µM calmidazolium after 2 days.
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Figure 25 Af3 aggregates grown in presence of 1 µM calmidazolium after 2 days.

77

(A)

200nm

(D)

200nm

200nm

(E)

200nm

200nm

Figure 26 AJ3 aggregates grown in presence of 100 µM calmidazolium after 14 days.
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Figure 27 Afl aggregates grown in presence of 10 µM calmidazolium after 14 days.
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Figure 28 Af3 aggregates grown in presence of 1 µM calmidazolium after 14 days.
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Figure 29 Seeding ability of AP aggregates grown in the presence of calmidazolium
chloride. Aggregates were collected as described in Materials and Methods. A - Kinetic
time course of AP deposition in microplate wells coated with AP aggregates grown in the
presence of 100 µM calmidazolium. B - Kinetic time course of AP deposition in
microplate wells coated with AP aggregates grown in the presence of 10 µM
calmidazolium. The microplate assay was conducted as described in Materials and
Methods. Data points shown represent aggregates grown in the presence of
calmidazolium for 2 days ( • ) and 14 days (■ ). Results are also shown for microplate
wells coated with control fibrils grown in the absence of calmidazolium for 2 days (• )
and 14 days (♦ ). Microplate wells coated with AP aggregates grown for only two days in
both the presence ( • ) and absence ( • ) of calmidazolium showed no ability to seed AP
deposition in the microplate assay, and both sets of data are buried in the baseline of the
figure. Results shown for microplate wells coated with control fibrils grown in the
absence of calmidazolium for 2 days (• ) and 14 days (♦) are the same in both A and B.
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Figure 30 Seeding ability of Af3/calmidazolium aggregates deposited in the microplate

assay. Prior to conducting the microplate assay (as described in Materials and Methods),
gelatin blocked microplate wells were incubated at37°C for 1 hour with either 10 nM AJ3
(non-biotinylated) plus 100 µM calmidazolium chloride ( ♦), only 10 nM AJ3 (non
biotinylated) (■), or only 100 µM calmidazolium chloride ( •) washed with buffer, and
conducting the microplate assay as described in Materials and Methods. The standard
microplate assay was also conducted in wells coated with 100 ng of fibrils ( • ) (as
described in Materials and Methods). No appreciable deposition of biotinyl-AJ3 can be
seen in any of the pre-incubated wells.
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Figure 31 Deuterium content vs. time for deuterated AP aggregates. Data points

represent the extent of deuteration of AP aggregates grown in the presence of 100 µM
calmidazolium (A) and 10 µM calmidazolium (B) for 2 days, 4 days, and 14 days. The
same set of control data points is shown on each graph, representing AP fibrils grown
using the same AP stock solution as the calmidazolium aggregates (AP 1-40 normal(d=14
control)) and hydrogen/deuterium exchange data obtained previously for wildtype
AP(l -40) fibrils (AP l -40 normal (8/24/01, d=12)). All aggregates were collected and
washed as described in Materials and Methods. Deuteration of AP aggregates grown in
the presence of calmidazolium after 4 days is about as great as that of AP protofibrils
collected after 2 days (� 20 deuteriums) (I. Kheterpal and H. Lashuel, unpublished). After
14 days, 10 µM calmidazolium AP aggregates show the same amount of deuteration as
AP fibrils (� 10 deuteriums) while 100 µM calmidazolium AP aggregates remain open to
hydrogen/deuterium exchange (� 20 deuteriums). (figure courtesy of I. Kheterpal,
unpublished).
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